Centers | ||
Edinburgh Drug Discovery | EU-OPENSCREEN | UCSC Chemical Screening Center |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all UCSF And Genentech to Develop Drugs to Treat Neurodegenerative DiseasesUniversity of California, San Francisco (UCSF) and Genetech have entered into a research collaboration to develop drugs to treat neurodegenerative diseases. Genetech will be providing funding to researchers at UCSF Small Molecule Discovery Center... View all |
No EVENTS for listing |
No Job Posts |


